A substitution at the cytoplasmic tail of the spike protein enhances SARS-CoV-2 infectivity and immunogenicity
Yuhan Li,Xianwen Zhang,Wanbo Tai,Xinyu Zhuang,Huicheng Shi,Shumin Liao,Xinyang Yu,Rui Mei,Xingzhao Chen,Yanhong Huang,Yubin Liu,Jianying Liu,Yang Liu,Yibin Zhu,Penghua Wang,Mingyao Tian,Guocan Yu,Liang Li,Gong Cheng
DOI: https://doi.org/10.1016/j.ebiom.2024.105437
IF: 11.205
2024-11-13
EBioMedicine
Abstract:Summary Background Global dissemination of SARS-CoV-2 Omicron sublineages has provided a sufficient opportunity for natural selection, thus enabling beneficial mutations to emerge. Characterisation of these mutations uncovers the underlying machinery responsible for the fast transmission of Omicron variants and guides vaccine development for combating the COVID-19 pandemic. Methods Through systematic bioinformatics analysis of 496,606 sequences of Omicron variants, we obtained 40 amino acid substitutions that occurred with high frequency in the S protein. Utilising pseudoviruses and a trans -complementation system of SARS-CoV-2, we identified the effect of high-frequency mutations on viral infectivity and elucidated the molecular mechanisms. Finally, we evaluated the impact of a key emerging mutation on the immune protection induced by the SARS-CoV-2 VLP mRNA vaccine in a murine model. Findings We identified a proline-to-leucine substitution at the 1263rd residue of the Spike protein, and upon investigating the relative frequencies across multiple Omicron sublineages, we found a trend of increasing frequency for P1263L. The substitution significantly enhances the capacity for S-mediated viral entry and improves the immunogenicity of a virus-like particle mRNA vaccine. Mechanistic studies showed that this mutation is located in the FERM binding motif of the cytoplasmic tail and impairs the interaction between the S protein and the Ezrin/Radixin/Moesin proteins. Additionally, this mutation facilitates the incorporation of S proteins into SARS-CoV-2 virions. Interpretation This study offers mechanistic insight into the constantly increasing transmissibility of SARS-CoV-2 Omicron variants and provides a meaningful optimisation strategy for vaccine development against SARS-CoV-2. Funding This study was supported by grants from the National Key Research and Development Plan of China ( 2021YFC2302405 , 2022YFC2303200 , 2021YFC2300200 and 2022YFC2303400 ), the National Natural Science Foundation of China ( 32188101 , 32200772 , 82422049 , 82241082 , 32270182 , 82372254 , 82271872 , 82341046 , 32100755 and 82102389 ), Shenzhen Medical Research Fund ( B2404002 , A2303036 ), the Shenzhen Bay Laboratory Startup Fund ( 21330111 ), Shenzhen San-Ming Project for Prevention and Research on Vector-borne Diseases ( SZSM202211023 ), Yunnan Provincial Science and Technology Project at Southwest United Graduate School ( 202302AO370010 ). The New Cornerstone Science Foundation through the New Cornerstone Investigator Program, and the Xplorer Prize from Tencent Foundation.
medicine, research & experimental